WCG

What WCG does

WCG (WCG Clinical Services) is a privately-held clinical research solutions provider founded in 1969 as the first independent Institutional Review Board and headquartered in Cary, North Carolina. The company supports over 4,000 active trials across 130+ countries and is the trusted partner for 94% of all FDA-approved therapeutic agents in the last five years. WCG employs 1,700+ staff across 18 countries and serves pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and research sites through a horizontally-segmented portfolio spanning IRB and IBC ethical review, endpoint adjudication and data monitoring committees, site enablement, clinical trial training, participant recruitment and retention, and benchmarking services.

The company's core technology asset is the ClinSphere platform, a unified cloud environment built on four architectural pillars (Interoperability, Collaboration, Agility, and Continuity) that connects sites, sponsors, CROs, and participants under a single login. ClinSphere integrates purpose-built AI/ML modules including eReview Manager for IRB workflows, Total Feasibility for site selection (with proprietary investigator match scores across 80+ countries), Total Enrollment for participant recruitment, Trial IntelX for AI-powered trial design, AIMS for endpoint adjudication, and CTMS solutions. Supporting infrastructure includes InvestigatorSpace (525K+ active users), SafetyVigilance (250+ country distribution), and the Avoca Quality Consortium's library of 1,500+ tools and templates. The WCG Site Network of 470-500+ site locations and 1,000+ investigators, combined with the 200+ member Avoca Quality Consortium, creates a multi-sided network spanning the clinical research ecosystem.

WCG generates revenue through a hybrid model combining subscription-based SaaS licensing of ClinSphere modules, professional services (IRB and IBC review, endpoint adjudication, statistical consulting, training, and recruitment), and consortium or site network membership fees. Pricing is custom-negotiated under a quote-based enterprise sales motion delivered through field representatives, with multi-year contracts typical. The company has executed a sustained acquisition strategy under PE sponsorship (Leonard Green & Partners, Arsenal Capital Partners, Novo Holdings since 2019), including Intrinsic Imaging (2021), The Avoca Group (2021), VeraSci (2021), Array (2024), and The Contract Network (2026), while divesting its eCOA business to Clario in 2025 to refocus on its core ethical review and AI-enabled platform.

Name

WCG

Legal name

WCG Clinical

Website

https://wcgclinical.com

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

WCG is a privately-held clinical research solutions provider founded in 1969 that supports over 4,000 trials in 130+ countries through its ClinSphere AI-enabled platform, serving pharmaceutical companies, biotech firms, CROs, and research sites with IRB review, site enablement, training, recruitment, and endpoint adjudication services.

Ownership category

akta.pro rank

Product category

Clinical Research Technology / Clinical Trial Solutions

NAICS

Scientific Research and Development Services (5417), Computer Systems Design and Related Services (54151)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370), Services-Health Services (8000)

akta.pro primary industry

Regulatory Submissions & Clinical Content Management (eCTD/Publishing) (HLACAOAN)

akta.pro secondary industries

Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA), Web Content Management (WCM) & Experience Platforms (Content Services) (HDAEAGAK)

Keywords

• Clinical trial solutions
• IRB review services
• Clinical research technology
• Site enablement platform
• Clinical trial management

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Solutions - Professional Services & SaaS: WCG generates revenue through a hybrid model combining subscription-based SaaS technology solutions (ClinSphere platform and its modules), professional services (IRB review, IBC review, endpoint adjudication, DMC, statistical consulting, training, site enablement, recruitment & retention), and per-study or per-transaction fees. The company serves pharmaceutical, biotech, and medical device companies as well as CROs and research sites with a mix of recurring platform subscriptions and project-based service engagements.
2. Technology Platform Licensing & Subscriptions: Revenue from licensing the ClinSphere platform and its constituent modules (Total Feasibility, Total Enrollment, eReview Manager, AIMS, InvestigatorSpace, CTMS solutions) on a subscription basis. Clients access platforms via web logins with enterprise-level pricing tiers based on study volume or organization size.
3. Site Network & Consortium Membership: The WCG Site Network connects sponsors and CROs with 500+ site locations; the Avoca Quality Consortium provides 200+ member organizations with access to 1,500+ tools and templates. These generate revenue through membership and service fees.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels9 records

Core offering

WCG provides technology-enabled clinical research solutions spanning independent ethical review (IRB and IBC), endpoint adjudication, data monitoring, clinical trial training, participant recruitment and retention, and site enablement. Its ClinSphere platform unifies these capabilities with AI/ML across trial design, feasibility, enrollment, IRB workflows, and CTMS. The company serves pharmaceutical sponsors, biotech firms, CROs, and research sites across 130+ countries, supporting over 4,000 trials.

Product overview

WCG offers a platform-plus-modules architecture centered on its ClinSphere technology platform, which integrates AI capabilities across clinical trial operations. The core platform unifies site enablement, study planning and review, participant recruitment and retention, and data intelligence through interconnected modules including Total Feasibility for site selection, eReview Manager for IRB workflows, Total Enrollment for recruitment management, and Trial IntelX for AI-powered trial design. Supporting services include IRB/IBC review, Endpoint Adjudication, Data Monitoring Committees, Total Training for clinical education, the Site Network of 500+ locations, and the Avoca Quality Consortium for industry collaboration. WCG's eCOA business was sold to Clario in 2025. The company supports over 4,000 trials in 130 countries and has been the trusted partner for 94% of FDA-approved therapeutic agents in the last five years.

Differentiator

Problem solved

Functional benefit

Brands

• ClinSphere: AI-powered interoperable technology platform connecting sites, sponsors, CROs, and participants for end-to-end clinical trial management
• WCG CenterWatch
• WCG Avoca Quality Consortium
• InvestigatorSpace
• IRB Connexus
• eReview Manager
• Total Enrollment
• Total Training
• Total Feasibility
• AIMS
• IRBNet
• SafetyVigilance
• eResearch CTMS

Products and services

• ClinSphere

Quantifiable outcome

• 29% faster study start-up timelines when working with the WCG Site Network
• +14 more outcomes

Named customers14 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature12 records

Partnerships

Ten partnerships are on record, tiered core, major and supporting.

• The Contract NetworkcoreStrategic or Co-development Partner · 1 April 2026WCG announced an agreement to acquire The Contract Network, an AI-powered contract and study start-up technology company, in April 2026. The acquisition extends WCG's ClinSphere platform with specialized AI capabilities for analyzing and surfacing inconsistencies in study documents, enabling proactive issue identification and more predictable workflows. Once integrated, ClinSphere will offer what WCG claims is the industry's most comprehensive AI-enabled platform for clinical research operations, spanning predictive trial design, site feasibility, participant enrollment, ethical review, and contract and budget intelligence. WCG CEO Sam Srivastava stated this acquisition accelerates their AI roadmap and creates the industry's most comprehensive AI-enabled platform.
• ClariomajorOthers · 1 January 2025In 2025, Clario entered into a definitive agreement to acquire WCG's electronic clinical outcome assessments (eCOA) business, which was completed in May 2025. The acquisition enhanced Clario's neuroscience capabilities in clinical trial data solutions. WCG divested its eCOA business (products including Virgil, Pathway, and ALearn) to Clario, strengthening Clario's scientific expertise in neurology, psychiatry, neuropathic pain, and rare diseases. WCG's eCOA/ePRO products are now supported by Clario.
• Array (from Lightview Capital)coreStrategic or Co-development Partner · 1 August 2024WCG acquired Array, a content engagement partner for life sciences events, from Lightview Capital in August 2024. The acquisition introduced an integrated clinical research training solution, combining Array's technology and analytics with WCG's training capabilities. The combined offering aims to improve training effectiveness, accelerate trial start-up, and enhance research quality and safety in clinical trials. Array was part of Lightview Capital's portfolio since 2019.
• Florence HealthcaresupportingTechnology or Integration · 1 November 2023WCG partnered with Florence Healthcare to advance site enablement in clinical research. The partnership enables seamless integration between Florence Healthcare's site enablement technology and WCG's clinical trial solutions ecosystem, helping sites optimize their operations and improving connectivity between sponsors, CROs, and research sites.
• Intrinsic ImagingcoreStrategic or Co-development Partner · 1 July 2021WCG acquired Intrinsic Imaging, a global provider of medical imaging core lab services, in July 2021. The acquisition enhanced WCG's clinical trial offerings in drug, medical device, and artificial intelligence research, reinforcing WCG's scientific and regulatory capabilities. Intrinsic Imaging brings ISO-certified quality management and broad therapeutic expertise, including a full-service imaging core lab with 200+ board-certified radiologists focused on areas like hematology/oncology.
• Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard (MRCT Center)coreStrategic or Co-development PartnerWCG partnered with the MRCT Center to develop a framework for ethical IRB review of AI-driven research protocols. This represents the first multi-stakeholder consortium co-led by WCG to address ethical challenges in AI-based clinical research. The partnership addresses the need for guidance on ethical oversight as AI adoption increases in clinical trials, and WCG published the resulting Framework for Review of Clinical Research Involving AI to advance ethical oversight in the industry.
• YunusupportingTechnology or IntegrationYunu partnered with WCG and IgniteData to transform clinical trial imaging through an integrated, real-time platform. The partnership aims to improve clinical trial imaging services by combining Yunu's imaging capabilities with WCG's clinical trial platform ecosystem and IgniteData's data integration technology.
• IgniteDatasupportingTechnology or IntegrationIgniteData partnered with WCG and Yunu to improve clinical trial imaging services through an integrated, real-time platform. The partnership integrates IgniteData's data integration technology with WCG's platform ecosystem to streamline clinical trial imaging workflows.
• MercksupportingGTM or Marketing PartnerWCG has an active partnership with Merck, evidenced by joint webinar content titled 'Moving Trials Forward: Inside the Merck and WCG Partnership that Unblocks Bottlenecks and Empowers Sites.' The partnership focuses on identifying and addressing bottlenecks in clinical trial execution and empowering research sites.
• Dr. Vince Clinical ResearchsupportingStrategic or Co-development PartnerWCG IRB expanded its Phase I review services through a partnership with Dr. Vince Clinical Research. This partnership strengthens WCG's capabilities for reviewing Phase I and First-in-Human (FIH) studies, which present unique challenges including residential studies requiring participant monitoring.

Scale indicators28 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Parexel International: Large global CRO providing clinical operations, biostatistics, and regulatory services; overlaps with WCG's IRB review, EAC, DMC, and statistical consulting capabilities as part of full-service bids.
• ICON plc: Global CRO offering full-service clinical operations and technology-enabled trial delivery; competes with WCG's professional services and site network offerings for sponsor outsourcing budgets.
• IQVIA: Global CRO and life sciences technology incumbent offering full-service clinical operations plus Rave/Oracle-backed analytics; competes with WCG's professional services and ClinSphere modules as part of broader enterprise deals.
• Oracle Health Sciences: Provides Oracle Clinical One and Sievo-adjacent life sciences analytics; competes with WCG's CTMS, feasibility, and analytics capabilities as a broad enterprise platform vendor.
• Worldwide Clinical Trials: Mid-to-large global CRO with therapeutic-area expertise in CNS and rare disease; overlaps with WCG's professional services and the previous employer of incoming CFO Anthony Doyle, indicating direct talent and customer overlap.

Direct peers

• Advarra: Direct peer providing central IRB services, IBC review, and site enablement technology for clinical trials; competes head-to-head with WCG IRB and the broader ClinSphere site enablement stack.
• Veeva Systems: Public clinical-trial and life sciences SaaS provider (Veeva Vault CTMS, Vault eTMF, Vault CDB); competes with WCG's CTMS and clinical operations modules within the same sponsor buyer base.
• Medidata Solutions (Dassault Systèmes): Clinical trial SaaS platform offering Rave EDC, Rave CTMS, and trial design tools; directly competes with WCG's CTMS, Total Enrollment, and Trial IntelX offerings for sponsor enterprise software budgets.
• Clario: Clinical trial technology provider that acquired WCG's eCOA/ePRO business in May 2025; now serves the same sponsor customers with adjacent eCOA, imaging, and endpoint solutions that overlap WCG's historical stack.

Emerging players

• Florence Healthcare: Site enablement technology provider with eBinders, eISF, and Site Link; competes with WCG's site enablement, CTMS, and document workflow modules for the same research site customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/WCGClinical
• LinkedInlinkedin.com/company/wirb-copernicus-group
• Xx.com/wcgclinical

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A15 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WCG